US › Healthcare

Kazia Therapeutics Ltd ADR (KZIA)

US · Healthcare · Biotechnology

$12.31-0.81%
Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Net profit
$-12.3M
Profit YoY
-39.7%
EPS
$-7.64
EPS estimate
$-221.00

EPS came in at -7.64 against a street estimate of -221.00 — a beat of 96.5%.

Key statistics

Market cap
$144.2M
Forward P/E
12.8
P/B
4.46
Book value
$2.86
EPS (TTM)
$-7.40
52-week high
$17.40
52-week low
$4.86
50-day MA
$13.07
200-day MA
$9.76
Beta
2.15

Analyst view

Analysts rate Kazia Therapeutics Ltd ADR a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $27.56.

Shareholding

Insiders
19.81%
Institutions
28.23%

Largest institutional holders

FundStake
Bleichroeder LP3.50%
Stonepine Capital Management Llc3.02%
Point72 Asset Management, L.P.1.75%
Balyasny Asset Management LLC1.69%
F.L.Putnam Investment Management1.25%
Velan Capital Investment Management LP1.18%
Dauntless Investment Group, LLC0.70%
Westside Investment Management, Inc.0.44%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kazia Therapeutics Ltd ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.